BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31751847)

  • 1. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study.
    Oh PJ; Lee JR; Kim SK; Kim JH
    Eur J Oncol Nurs; 2020 Feb; 44():101676. PubMed ID: 31751847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
    Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
    J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Disturbance in ADL from Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Cancer Patients: The Mediating Effect of Psychological Distress].
    Kim KY; Lee SH; Kim JH; Oh PJ
    J Korean Acad Nurs; 2015 Oct; 45(5):661-70. PubMed ID: 26582111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study.
    Tabata A; Kanai M; Horimatsu T; Tsuboyama T; Matsushima K; Kato T
    Support Care Cancer; 2018 Jul; 26(7):2397-2405. PubMed ID: 29423680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
    Hines RB; Schoborg C; Sumner T; Zhu X; Elgin EA; Zhang S
    Support Care Cancer; 2023 Jun; 31(7):386. PubMed ID: 37294347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro).
    Gehr NL; Karlsson P; Timm S; Christensen S; Hvid CA; Peric J; Hansen TF; Lauritzen L; Finnerup NB; Ventzel L
    BMC Cancer; 2024 Feb; 24(1):168. PubMed ID: 38308227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale: a prospective cohort study.
    Gu Z; Chen C; Gu J; Song Z; Wei G; Cai G; Shu Q; Zhu L; Zhu W; Deng H; Li S; Chen A; Yin Y; Wu Q; Zhu H; Li G; Dai A; Huo J
    BMC Cancer; 2023 Nov; 23(1):1109. PubMed ID: 37964212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study.
    Delmotte JB; Beaussier H; Auzeil N; Massicot F; Laprévote O; Raymond E; Coudoré F
    Cancer Treat Res Commun; 2018; 17():31-36. PubMed ID: 30343217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy.
    Chen SJ; Chen LH; Yeh YM; Lin CK; Lin PC; Huang HW; Shen MR; Lin BW; Lee JC; Lee CC; Lee YF; Chiang HC; Chang JY
    Theranostics; 2021; 11(10):4672-4687. PubMed ID: 33754020
    [No Abstract]   [Full Text] [Related]  

  • 10. A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system.
    Coolbrandt A; Tobback H; Govaerts R; Vandezande L; Vinckx M; Laenen A; Wildiers H; Verslype C; Dekervel J; Van Herpe F; Van Cutsem E
    ESMO Open; 2023 Apr; 8(2):101205. PubMed ID: 37018872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
    Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
    BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors.
    Tofthagen C; Donovan KA; Morgan MA; Shibata D; Yeh Y
    Support Care Cancer; 2013 Dec; 21(12):3307-13. PubMed ID: 23903798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies.
    Miyamoto T; Domoto R; Sekiguchi F; Kamaguchi R; Nishimura R; Matsuno M; Tsubota M; Fujitani M; Hatanaka S; Koizumi Y; Wang D; Nishibori M; Kawabata A
    J Pharmacol Sci; 2022 Mar; 148(3):315-325. PubMed ID: 35177211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New diagnostic measures of oxaliplatin-induced peripheral sensory neuropathy.
    Szpejewska JE; Yilmaz M; Falkmer UG; Arendt-Nielsen L; Mørch CD
    Cancer Treat Res Commun; 2022; 31():100543. PubMed ID: 35255440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer.
    Hsu SY; Huang WS; Lee SH; Chu TP; Lin YC; Lu CH; Beaton RD; Jane SW
    Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12976. PubMed ID: 30536809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laser acupuncture attenuates oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a pilot prospective cohort study.
    Hsieh YL; Chou LW; Hong SF; Chang FC; Tseng SW; Huang CC; Yang CH; Yang CC; Chiu WF
    Acupunct Med; 2016 Oct; 34(5):398-405. PubMed ID: 27613370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.
    Lee S; Ma C; Shi Q; Kumar P; Couture F; Kuebler P; Krishnamurthi S; Lewis D; Tan B; Goldberg RM; Venook A; Blanke C; O'Reilly EM; Shields AF; Meyerhardt JA
    J Clin Oncol; 2023 Feb; 41(5):1079-1091. PubMed ID: 36367997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
    Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
    BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment.
    Kang L; Tian Y; Xu S; Chen H
    J Neurol; 2021 Sep; 268(9):3269-3282. PubMed ID: 32474658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life.
    Stefansson M; Nygren P
    Acta Oncol; 2016; 55(9-10):1227-1235. PubMed ID: 27550718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.